This is a significant pipeline de-risking event for AGMB. The Phase 1 data showing proof-of-mechanism and a clean safety profile at the selected Phase 2 dose (4.5 mg BID) substantially lowers the risk profile for the upcoming INSPIRIA study. Traders should watch for the initiation of the Phase 2 trial and any subsequent data readouts, which will be the next major catalyst. The stock may re-rate as the probability of success for AGMB-447 increases.
Price Chart
Executive Summary
No summary provided
Key Facts
- Phase 1 data for AGMB-447 in 10 IPF patients showed generally favorable safety and tolerability at 4.5 mg BID.
- pSMAD3 reduction in BAL cells of >50% was achieved at the 4.5 mg BID dose, indicating robust target engagement.
- Pharmacokinetic profile confirmed lung restriction: BAL fluid levels above IC90 for at least 6 hours and above IC50 for 24 hours at 4.5 mg BID.
- Phase 2 INSPIRIA study designed as a 24-week, randomized, double-blind, placebo-controlled trial in ~120 IPF patients with FVC as primary endpoint.
- Clinical Trial Application (CTA) for INSPIRIA has been submitted; company intends to initiate the study before year-end 2026.
- AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβR1) for Idiopathic Pulmonary Fibrosis.
Financial Impact
Positive Phase 1 data and Phase 2 design de-risk the lead pipeline asset AGMB-447 in a large market (IPF affects ~255,000 patients in US, Japan, and EU4+UK). No financial figures disclosed.
Risk Factors
- Phase 2 INSPIRIA study may fail to meet its primary endpoint (FVC change at Week 24).
- Higher incidence of adverse events (cough, bronchospasm) at the 6 mg BID dose could indicate a narrow therapeutic window.
- Competition from approved IPF therapies (pirfenidone, nintedanib) and other pipeline candidates.
- Company is pre-revenue and relies on capital markets for funding; no cash runway data provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-107500 |
| Document: tm2625366d1_6k.htm | 0001104659-26-107500 |
| Document: 0001104659-26-107500-index-headers.html | 0001104659-26-107500 |
| Document: 0001104659-26-107500-index.html | 0001104659-26-107500 |
| Document: 0001104659-26-107500.txt | 0001104659-26-107500 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Insider Buy | $9.26 | awaiting T+5 | — | $8.60 (−7.13%) |
Oct 13, 2026 13d ago | 6-K | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $8.60 (−1.04%) |
Oct 13, 2026 13d ago | Press Release | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $8.60 (−1.04%) |
Oct 1, 2026 26d ago | 6-K | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $8.60 (−0.58%) |
Oct 1, 2026 26d ago | Press Release | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $8.60 (−0.58%) |
Sep 14, 2026 6w ago | 6-K | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $8.60 (−29.28%) |
Sep 14, 2026 6w ago | Press Release | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $8.60 (−29.28%) |
Sep 11, 2026 6w ago | 6-K | $12.28 $11.70 | ▼ −4.72% | ▼ −4.83% | $8.60 (−29.97%) |
Aug 10, 2026 11w ago | 6-K | $14.85 $13.73 | ▼ −7.54% | ▼ −7.14% | $8.60 (−42.09%) |
Jun 23, 2026 17w ago | 6-K | $12.68 $11.87 | ▼ −6.39% | ▼ −8.10% | $8.60 (−32.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers